Drug & intervention

osimertinib 80 MG

RxCUI 1721580

Clinical trials6

Recruiting2

Related conditions7

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

6 shown

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCNCT07058519 · 2025-09-23

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)NCT04591002 · 2022-09-11

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLCNCT06557096 · 2024-08-20

NOT_YET_RECRUITING

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLCNCT05583409 · 2023-01-01

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC PatientsNCT04184921 · 2019-01-01

First Line Osimertinib in the Real World: an Inter-regional Prospective StudyNCT04965701 · 2018-06-01

Conditions being studied

EGF-R Positive Non-Small Cell Lung Cancer2 Circulating Tumor Cell1 Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)1 Lung Cancer1 Lung Cancer Non-small Cell Stage IV1 Non Small Cell Lung Cancer1 Stage IV Non-small Cell Lung Cancer1

Research locations

ChongqingChongqing Municipality, China1 PadovaItaly1 SeoulSouth Korea1 ShanghaiShanghai Municipality, China1 WuhanHubei, China1

Leading sponsors

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1 Istituto Oncologico Veneto IRCCS1 Li Zhang1 Samsung Medical Center1 Second Affiliated Hospital of Nanchang University1 Shanghai Chest Hospital1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.